Dasher Neuroscience Press Releases
Breaking News and Milestones

Corporate News

Dasher Neuroscience to Exhibit at BIO Asia-Taiwan
Visit our booth to discuss partnership opportunities.
Dates: 16…
Dasher Neuroscience to Exhibit at BIO International Convention
Dasher Neuroscience will participate in the BIO International…
Clinical and Research Updates

YA-101 Granted Orphan Drug Designation by the EU EMA for the Treatment of Multiple System Atrophy
TAIPEI, January 14, 2026 — YODA-KY (7829) announced today (14th)…
YA-101 Receives Orphan Drug Designation in Japan, Following U.S. FDA Fast Track, Advancing Global Development Plans
TAIPEI, December 23, 2025 — YODA-KY (7829) announced today…
New Drug YA-101 Granted US FDA “Fast Track Designation” for the Treatment of Multiple System Atrophy
TAIPEI, December 22, 2025 —YODA-KY (7829) announced today (22nd)…
New Collaborations and Agreements

Dasher Neuroscience, Taiwan’s First: AI-Developed Drug Prioritized by iLCT for Parkinson’s Disease Development; Signs MOUs with Australia and New Zealand to Expand Clinical Reach
TAIPEI, March 27, 2026 — Focusing on the use of artificial…

Dasher Neuroscience Signs MOU with Norwegian Research Center to Join the Platform Trial HYDRA and Advance AI-Driven Parkinson’s Drug Development in Europe
Release Date: March 27, 2026
Focusing on the use…
